NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 348 filers reported holding NEKTAR THERAPEUTICS in Q4 2018. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $32,351,000 | -28.4% | 1,950 | 0.0% | 0.01% | -28.6% |
| Q2 2020 | $45,162,000 | +23.5% | 1,950 | +225.0% | 0.01% | +40.0% |
| Q3 2018 | $36,576,000 | +66.5% | 600 | +33.3% | 0.01% | +66.7% |
| Q2 2018 | $21,974,000 | -54.0% | 450 | 0.0% | 0.01% | -57.1% |
| Q1 2018 | $47,817,000 | +77.9% | 450 | 0.0% | 0.01% | +100.0% |
| Q4 2017 | $26,874,000 | -65.5% | 450 | -86.2% | 0.01% | -65.0% |
| Q3 2017 | $78,000,000 | +22.8% | 3,250 | 0.0% | 0.02% | +53.8% |
| Q2 2017 | $63,538,000 | -12.7% | 3,250 | +4.8% | 0.01% | -7.1% |
| Q1 2017 | $72,757,000 | -27.0% | 3,100 | -55.7% | 0.01% | -17.6% |
| Q2 2016 | $99,610,000 | -57.9% | 7,000 | -59.3% | 0.02% | -61.4% |
| Q1 2016 | $236,500,000 | -18.4% | 17,200 | 0.0% | 0.04% | -12.0% |
| Q4 2015 | $289,820,000 | – | 17,200 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |